- Dispute with U.S. Conerning Data Exclusivity
- USTR Documents
- March 4, 2005.
Letter from 19 Senators and Representatives to Acting USTR Peter Allgeier.
- No date. Report by Mark S Cohen and Tal Frieman.
Data Exclusivity in Israel.
- News Stories
- March 28, 2005. Navit Zomer for the Yediot Ahronot.
Ethical drugs will be protected for 5 years.
- March 24, 2005. Navit Zomer for Y-Net news.
Israel may adopt drug exclusivity policy.
- March 7, 2005. Hadas Manor for Globes.
19 US Senators and Representatives Come Out in Support of Israeli Pharma.
- February 7, 2005. Financial Times.
Drugs IP/ Israel vs. The world.
- December 2, 2004. Hadas Manor for Globes.
Teva exec: US stance on IP impudent.
- December 2, 2004. Hadas Manor for Globes.
Far Apart - The breakdown of the Israel-US talks on drugs IP is costly
for both sides.
- September 26, 2004. Itamar Levin for Globes.
Drugs vote Republican - Which may be why the US is pressing Israel so hard on IP.
- September 19, 2004. Ran Dagoni for Globes.
US turns up IP heat - "Israel could be reinstated on the priority watch list."
- September 9, 2004. mati Wagner for the Jerusalem Post.
Intellectual property bill risks US censure.
- July 12, 2004. Hadas Manor for Globes.
Intellectual Property Dispute With U.S. Still Unresolved.
- July 1, 2004. Hadas Manor for Globes.
US to Israel: Grant 5-year exclusivity for ethical drugs.
- May 20, 2004. Mati Wagner for the Jerusalem Post.
US to advise international drug firms to pull R&D.
- April 25, 2004. Hadas Manor for Globes.
Gov't postpones data exclusivity law vote because of US pressure.
- April 1, 2004. Hadas Manor and Avishay Ovadia for Globes.
Olmert: US intellectual property critique isn't against Teva.
- March 31, 2004. Ran Dagoni for Globes.
US set to put Israel back on intellectual property watch list.
- Older News Stories
- 2000, May 31, Haim Shadmi, in Ha'aretz,
Beilin holds off approving new rules for drug imports.
- 2000, May 31, Ha'aretz Editorial,
Putting pharmacy prices to rest.
- 2000, May 30, Judy Siegel, in The Jerusalem Post,
New regulations make drug market more competitive.
- 1998. Israel Shachter,
Amendment of the Israel Patent Law In Order To Provide for Non-Infringing
Pre-expiry Exploitation of Patents and for Their Extension of Term.
- 1998, Dr. Ilan Cohen,
Israel Patent Term Extension Order.
- March 7, 1998, Judy Siegel-Itzkovich, in British Medical Journal, Israel's patent law
criticised.
- 1997, Michael Cohen,
Experimental use of patented invention
for submission to regulatory authorities does infringe.
- October 1997, Michael Cohen,
Compulsory Licence for the Manufacture of a Hepatitis B
Vaccine: Exploitation of the Invention for R&D Prior to
Compulsory Licence Proceedings in Israel,
from Patent World.
- December 30, 1997, Nechama Goldman
Between a patent and a hard place.
This article discusses the dispute over Teva's rights to use
patents for research purposes prior to the expiration of the patent.
Because Israel did not have a Bolar exemption at the time,
Teva received compulsory licenses. Michael Cohen is quoted,
and the report also says Dr. Cohen's firm represents
Ciba Geigy, Merck, and Hoffman LaRoche in patent disputes.
- 1996. Dr. Michael Cohn and David Gila.
End of the Road for Israel's
Compulsory Licenses?
- US Government Documents
- PhRMA Submissions on Israel
| CPT home page | CPT Intellectual Property page | CPT Health Care page |